Delivery with Polycations Extends the Immunostimulant Ribomunyl® into a Potent Antiviral Toll-Like Receptor 7/8 Agonist
Antiviral Therapy2011Vol. 16(5), pp. 751–758
Citations Over Time
Stephan Herberhold, Christoph Coch, Thomas Zillinger, Benjamin Hommertgen, Nicolas Busch, Christine Schuberth, Evelyn Hartmann, Vera Wimmenauer, Cristina Amparo Hagmann, Bastian Lüdenbach, Martin Schlee, Friedrich Bootz, Gunther Hartmann, Winfried Barchet
Abstract
Ribomunyl is, in principle, able to potently induce antiviral interferon-α and interleukin-12 via TLR7 and TLR8, respectively, but only when formulated in a complex with cationic polypeptides.
Related Papers
- → Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance(2011)84 cited
- → Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7(2016)19 cited
- → Precise determination of toll-like receptor (TLR) 7 expression in multiple human tumor types(2014)
- → 653 TOLL-LIKE RECEPTOR-DEPENDENT IFN I AND III SUBTYPES INDUCTION IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM PATIENTS WITH HCV INFECTION(2009)
- Advance in toll-like receptor 7-mediated antiviral innate immune responses(2010)